Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go

Journal of Hematology & Oncology

Xiao-Jun Huang¹  Meng Lv¹ 

[1] Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Beijng 100044, China

关键词: Elderly patients;    GVHD;    Relapse;    Haploidentical;    Allo-HSCT;    China;   

Others  :  822546
DOI  :  10.1186/1756-8722-5-10

 received in 2012-02-09, accepted in 2012-03-18,  发布年份 2012

【 摘 要 】

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.

【 授权许可】

   
2012 Lv and Huang; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Lu DP, Guo NL, Jin NR, Zheng H, Lu XJ, Shi Q, Shan FX, Jiang B, Tang H, Liu MY: Allogeneic bone marrow transplantation for the treatment of leukemia. Chin Med J (Engl) 1990, 103:125-130.
• [2]Xu LP, Huang XJ: Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group. Chin Med J (Engl) 2011, 124:2548-2555.
• [3]Pasquini MCWZ: Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. [http://www.cibmtr.org] webcite
• [4]Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, et al.: Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011, 117:3032-3040.
• [5]Huang XJ: Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol 2008, 1:27. BioMed Central Full Text
• [6]Fuchs EJ, Huang XJ, Miller JS: HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:S57-S63.
• [7]Reisner Y, Hagin D, Martelli MF: Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011, 118:6006-6017.
• [8]Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, et al.: Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
• [9]Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, et al.: Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
• [10]Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, et al.: Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007, 25:690-697.
• [11]Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC: Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 2008, 112:2232-2241.
• [12]Federmann B, Bornhauser M, Kordelas L, Beelen DW, Stuhler G, Schwerdtfeger R, Stelljes M, Behre G, Christopeit M, Faul C, et al.: Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: clinical outcome and immune reconstitution. ASH Annual Meeting Abstracts 2009, 114:1203.
• [13]Kurokawa T, Ishiyama K, Ozaki J, Yamashita Y, Iwaki N, Saito C, Arahata M, Kaya H, Yoshida T: Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Int J Hematol 2010, 91:661-669.
• [14]Huang XJ: Long Term Follow-up of Haploidentical Hematopoietic Stem Cell Transplantation without in Vitro T Cell Depletion for the Treatment of Hematological Malignancies: 9-Year Experience of a Single Center. ASH Annual Meeting Abstracts 2011, 118:839.
• [15]Lee KH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, et al.: Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011, 118:2609-2617.
• [16]Huang W, Li H, Gao C, Bo J, Wang Q, Zhao Y, Jing Y, Wang S, Zhu H, Dou L, et al.: Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion 2012. doi: 10.1111/j.1537-2995.2011.03478.x
• [17]Hong JL: A brief introduction of the Chinese Marrow Donor Program. Hong Kong Med J 2009, 15:45-47.
• [18]Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, et al.: Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
• [19]Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, et al.: Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
• [20]Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H, Yu-Hong C, Jing-Zhi W, Yao C, Xiao-Hui Z, et al.: HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008, 40:444-455.
• [21]Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, Yu-Hong C, Wei H, Jing-Zhi W, Yao C, et al.: Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. clin cancer res 2009, 15:4777-4783.
• [22]Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX, Huang XJ: Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 2011, 17:821-830.
• [23]Guo M, Sun Z, Sun QY, Han Q, Yu CL, Wang DH, Qiao JH, Chen B, Sun WJ, Hu KX, et al.: A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant 2009, 15:930-937.
• [24]Han W, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Zhang XH, Chen YH, Wang FR, Wang Y: The efficacy and safety of mismatched hematopoietic stem cell transplantation for treatment of severe aplastic anemia. Zhonghua Nei Ke Za Zhi 2011, 50:287-290.
• [25]Lee KW, Oh DH, Lee C, Yang SY: Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005, 65:437-447.
• [26]Okamoto S: Current status of Japan marrow donor program (JMDP) and its roles in international cooperation. Int J Hematol 2002, 76(Suppl 1):310-311.
• [27]Trachtenberg E, Vinson M, Hayes E, Hsu YM, Houtchens K, Erlich H, Klitz W, Hsia Y, Hollenbach J: HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Tissue Antigens 2007, 70:455-463.
• [28]Wu GG, Deng ZH, Gao SQ, Cheng LH, Jin SZ, Zhou D, Li Z, Zou HY, Zhang X, Wei TL, et al.: Study of HLA polymorphism in the 6965 Han bone marrow registry donors. Zhonghua Xue Ye Xue Za Zhi 2004, 25:473-477.
• [29]Buhler S, Sanchez-Mazas A: HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PLoS One 2011, 6:e14643.
• [30]Jun HX, Jun CY, Yu ZX: In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004, 89:1517-1524.
• [31]Jun HX, Jun CY, Yu ZX: A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica 2005, 90:715-716.
• [32]Huang XJ, Chang YJ, Zhao XY: Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007, 17:193-197.
• [33]Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS: Rabbit ATG but not horse ATG promotes expansion of functional CD4 + CD25highFOXP3+ regulatory T cells in vitro. Blood 2008, 111:3675-3683.
• [34]Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
• [35]Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP: Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007, 21:848-851.
• [36]Chang YJ, Zhao XY, Huang XJ: Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008, 14:323-334.
• [37]Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, et al.: First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood 2011, 117:5257-5260.
• [38]Diamond HR, Ornellas MH, Orfao A, Gomes BE, Campos MM, Fernandez TS, da Silva RI, Alves G, Lage C, da Silva DA, et al.: Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. J Hematol Oncol 2011, 4:39. BioMed Central Full Text
• [39]Huang XJ: Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Pract Res Clin Haematol 2011, 24:351-358.
• [40]Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
• [41]Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX: Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009, 44:309-316.
• [42]Huang X, Guo N, Ren H, Zhang Y, Gao Z, Lu D: An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J (Engl) 2003, 116:736-741.
• [43]Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W: Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 92:414-417.
• [44]Huang XJ, Liu DH, Xu LP, Chen H, Han W, Liu KY, Lu DP: Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006, 20:365-368.
• [45]Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y, Han W, Chen H: Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008, 28:276-283.
• [46]Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ: Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012. doi:10.1182/blood-2011-09-380386
• [47]Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH, Han W, Shi HX, Liu KY: Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. J Clin Immunol 2008, 28:390-397.
• [48]Yang Y, Wang H, Yu H, Yeap BY, Liang T, Wang G, Cheng T, Yang YG: IFN-gamma promotes graft-versus-leukemia effects without directly interacting with leukemia cells in mice after allogeneic hematopoietic cell transplantation. Blood 2011, 118:3721-3724.
• [49]Wang Y, Xu LP, Liu KY, Liu DH, Wang J, Chen H, Chen YH, Han W, Huang XJ: Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility. Bone Marrow Transplant 2011, 46:892-898.
• [50]Wang Y, Xu LP, Liu DH, Chen H, Chen YH, Han W, Liu KY, Huang XJ: First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. Biol Blood Marrow Transplant 2009, 15:505-511.
• [51]Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, et al.: Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2011, 17:1-17.
• [52]Lai Y, Ma J, Schwarzenberger P, Li W, Cai Z, Zhou J, Peng Z, Yang J, Luo L, Luo J, et al.: Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Bone Marrow Transplant 2009, 43:61-67.
• [53]Fang J, Hu C, Hong M, Wu Q, You Y, Zhong Z, Li W, Zou P, Hu Y, Xia L: Prophylactic Effects of Interleukin-2 Receptor Antagonists against Graft-versus-Host Disease following Unrelated Donor Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant 2011. doi:10.1016/j.bbmt.2011.09.005
• [54]Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, et al.: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
• [55]Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, et al.: Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
• [56]Zhao F, Zhang Y, Wang H, Jin M, He S, Shi Y, Guo Y: Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. Blood 2011, 117:1723-1733.
• [57]Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, et al.: Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:273-279.
• [58]Zhang C, Chen XH, Zhang X, Gao L, Kong PY, Peng XG, Liang X, Gong Y, Wang QY: Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice. J Biol Chem 2011, 286:13723-13732.
• [59]Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Qian K, Liu M: Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4 + CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Transfusion 2011. doi: 10.1111/j.1537-2995.2011.03448.x
• [60]Chen W, Li M, Li Z, Yan Z, Cheng H, Pan B, Cao J, Chen C, Zeng L, Xu K: CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease. Immunol Lett 2012. doi:10.1016/j.imlet.2012.01.015
• [61]Marks DI: Treating the "older" adult with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010, 2010:13-20.
• [62]Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S: Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
• [63]Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, Liu GX, Sun WJ, Wei L, Sun XD, et al.: Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011, 117:936-941.